Tags » People Places Events

Guideline Critics Shift Attacks From Beta Blockers To Statins

With the release today of updated European and US guidelines the ongoing controversy regarding beta-blockers appears to be resolved. But that doesn’t necessarily mean there will be an outbreak of guideline peace and harmony. 94 more words

Policy & Ethics

Dutch Investigation Finds Serious Flaws In Influential New England Journal Of Medicine Study

Erasmus Medical Center says it has wrapped up its investigation of Don Poldermans, the disgraced cardiology researcher who was fired for research misconduct. The full extent of the misconduct has never been known, and from an examination of the Erasmus report it appears likely that it never will be known. 69 more words

Policy & Ethics

More Questions Raised About Boehringer Ingelheim's Pradaxa

Once again dabigatran (Pradaxa) has raised the wrath of the critics. Several articles and an editorial published today in The BMJ raise more questions and concerns about the drug, which is the first of the new oral anticoagulants. 59 more words

Policy & Ethics

FDA Once Again Reaches Conclusions At Odds With Its Own Staff

Once again the FDA has reached a conclusion that is directly opposed by some of its own scientists.  Last month the FDA affirmed the safety of olmesartan, a popular blood pressure lowering drug (sold as Benicar and other names). 105 more words

Policy & Ethics

FDA Places Clinical Hold On Phase 3 Trial Of Novel Anticoagulant

A highly promising novel anticoagulant system now appears to be in serious difficulty. Regado Biosciences announced today that the FDA had placed a “clinical hold” on patient enrollment and dosing in the  55 more words

Policy & Ethics

Controversial Trial Finds No Benefit For Expensive Medicines Company Drug

Although there is broad consensus in the medical community that primary PCI is the best treatment for heart attack patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. 43 more words

Policy & Ethics